Search results
AbbVie Inc. (NYSE:ABBV) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 4 days agoAbbVie Inc. (NYSE:ABBV) Q1 2024 Earnings Call Transcript April 26, 2024 AbbVie Inc. beats earnings...
Michael Burgess trades in AbbVie, IBM, iShares ETF, and Merck stocks By Investing.com
Investing.com· 8 hours agoMichael Burgess trades in AbbVie, IBM, iShares ETF, and Merck stocks
Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successors
CNBC· 3 days agoSales of AbbVie's Humira are plummeting as the once-top-selling drug fights competition from cheaper...
...NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims - Comfort Systems USA (NYSE:FIX), ...
Benzinga· 6 hours agoThe first-quarter 2024 earnings season is almost over as far as large drugmakers are concerned. Eli...
Earnings Beat: AbbVie Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Simply Wall St. via Yahoo Finance· 4 days agoAbbVie Inc. (NYSE:ABBV) investors will be delighted, with the company turning in some strong numbers...
Better Dividend Stock: AbbVie or Johnson & Johnson?
Motley Fool via Yahoo Finance· 6 days agoThere are many dividend stocks on the market, but few are as prominent as AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ). These companies have...
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
Zacks via Yahoo Finance· 3 days agoAbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you...
Investors Take AbbVie To The Woodshed. But Its Woes Are 'Unfounded.'Investors Take AbbVie To The...
Investor's Business Daily· 4 days agoOn Friday, AbbVie beat first-quarter expectations, largely on the back of its immunology franchise....
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Zacks via Yahoo Finance· 13 hours agoWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the...
AbbVie (NYSE:ABBV) Price Target Cut to $187.00
ETF DAILY NEWS· 3 days agoAbbVie (NYSE:ABBV – Get Free Report) had its target price cut by equities researchers at Barclays from $195.00 to $187.00 in a research report issued on Monday, Benzinga reports ...